A few months after the European Medicines Agency (EMA) approval of the treatment with pembrolizumab for cases of relapsed and/or metastatic HNSCC, we in our feasibility study analyzed the different protocols and interobserver reliability in PD-L1 testing. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.